![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
A Mechanistic SimCYP Simulation Evaluating Dolutegravir and Efavirenz Pharmacokinetics Following a Switch From Once-daily Efavirenz to Once-daily Dolutegravir
|
|
|
Reported by Jules Levin
15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19-21, 2014, Washington, DC
Grant Generaux,1 Ivy Song,2 Gary Bowers,1 and Stephen Piscitelli3
1Drug Metabolism and Pharmacokinetics; 2Clinical Pharmacology Modeling and Simulation;
3Infectious Disease Medicine Discovery and Development, GlaxoSmithKline, Research Triangle Park, NC
![Pharm1.gif](../images/052214/052214-7/Pharm1.gif)
![Pharm2.gif](../images/052214/052214-7/Pharm2.gif)
![Pharm3.gif](../images/052214/052214-7/Pharm3.gif)
![Pharm4.gif](../images/052214/052214-7/Pharm4.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|